Differential Diagnosis of Metabolic Myopathies

Ayşe KILIÇa

aAnkara Training and Research Hospital, Clinic of Pediatric Metabolism Diseases, Ankara, Türkiye

ABSTRACT
Metabolic myopathies are a group of inborn metabolic diseases due to defects in carbohydrates metabolism, lipids metabolism and mitochondrial respiratory chain causing energy deficiency. Skeletal muscles are primarily affected, though other systems may also be affected. Inherited myopathies including congenital myopathies, channelopathies, muscular dystrophies as well as acquired myopathies such as inflammatory myopathies, toxic myopathies, infectious myopathies, endocrine myopathies, should be considered for the differential diagnosis of metabolic myopathies.
Keywords: Congenital myopathy; muscular dystrophy; toxic myopathy; autoimmune myopathy

Referanslar

  1. Nagy H, Veerapaneni KD. Myopathy. [Updated 2023 Aug 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: [Link]
  2. Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford). 2015;54(1):50-63. [Crossref]  [PubMed]
  3. Mathis S, Tazir M, Magy L, Duval F, Le Masson G, Duchesne M, et al. History and current difficulties in classifying inherited myopathies and muscular dystrophies. J Neurol Sci. 2018;384:50-4. [Crossref]  [PubMed]
  4. North KN, Wang CH, Clarke N, Jungbluth H, Vainzof M, Dowling JJ, et al.; International Standard of Care Committee for Congenital Myopathies. Approach to the diagnosis of congenital myopathies. Neuromuscul Disord. 2014;24(2):97-116. [Crossref]  [PubMed]  [PMC]
  5. Laing NG, Wallgren-Pettersson C. 161st ENMC International Workshop on nemaline myopathy and related disorders, Newcastle upon Tyne, 2008. Neuromuscul Disord. 2009;19(4):300-5. [Crossref]  [PubMed]
  6. Zvaritch E, Kraeva N, Bombardier E, McCloy RA, Depreux F, Holmyard D, et al. Ca2+ dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods. Proc Natl Acad Sci U S A. 2009;106(51):21813-8. [Crossref]  [PubMed]  [PMC]
  7. Nance JR, Dowling JJ, Gibbs EM, Bönnemann CG. Congenital myopathies: an update. Curr Neurol Neurosci Rep. 2012;12(2):165-74. [Crossref]  [PubMed]  [PMC]
  8. Wallgren-Pettersson C, Sainio K, Salmi T. Electromyography in congenital nemaline myopathy. Muscle Nerve. 1989;12(7):587-93. [Crossref]  [PubMed]
  9. Munot P, Lashley D, Jungbluth H, Feng L, Pitt M, Robb SA, et al. Congenital fibre type disproportion associated with mutations in the tropomyosin 3 (TPM3) gene mimicking congenital myasthenia. Neuromuscul Disord. 2010;20(12):796-800. [Crossref]  [PubMed]
  10. Shieh PB. Muscular dystrophies and other genetic myopathies. Neurol Clin. 2013;31(4):1009-29. [Crossref]  [PubMed]
  11. Carter JC, Sheehan DW, Prochoroff A, Birnkrant DJ. Muscular Dystrophies. Clin Chest Med. 2018;39(2):377-89. [Crossref]  [PubMed]
  12. Mercuri E, Muntoni F. The ever-expanding spectrum of congenital muscular dystrophies. Ann Neurol. 2012;72(1):9-17. [Crossref]  [PubMed]
  13. LoMauro A, D'Angelo MG, Aliverti A. Sleep Disordered Breathing in Duchenne Muscular Dystrophy. Curr Neurol Neurosci Rep. 2017;17(5):44. [Crossref]  [PubMed]
  14. Finsterer J, Ramaciotti C, Wang CH, Wahbi K, Rosenthal D, Duboc D, et al. Cardiac findings in congenital muscular dystrophies. Pediatrics. 2010;126(3):538-45. [Crossref]  [PubMed]
  15. Cyrulnik SE, Fee RJ, Batchelder A, Kiefel J, Goldstein E, Hinton VJ. Cognitive and adaptive deficits in young children with Duchenne muscular dystrophy (DMD). J Int Neuropsychol Soc. 2008;14(5):853-61. [Crossref]  [PubMed]
  16. Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013;381(9869):845-60. [Crossref]  [PubMed]
  17. Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465-72. [Crossref]  [PubMed]  [PMC]
  18. Cannon SC. Pathomechanisms in channelopathies of skeletal muscle and brain. Annu Rev Neurosci. 2006;29:387-415. [Crossref]  [PubMed]
  19. Lehmann-Horn F, Rüdel R. Channelopathies: the nondystrophic myotonias and periodic paralyses. Semin Pediatr Neurol. 1996;3(2):122-39. [Crossref]  [PubMed]
  20. Sun C, Van Ghelue M, Tranebjærg L, Thyssen F, Nilssen Ø, Torbergsen T. Myotonia congenita and myotonic dystrophy in the same family: coexistence of a CLCN1 mutation and expansion in the CNBP (ZNF9) gene. Clin Genet. 2011;80(6):574-80. [Crossref]  [PubMed]
  21. Fontaine B. Periodic paralysis. Adv Genet. 2008;63:3-23. [Crossref]  [PubMed]
  22. Miller TM, Dias da Silva MR, Miller HA, Kwiecinski H, Mendell JR, Tawil R, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology. 2004;63(9):1647-55. [Crossref]  [PubMed]
  23. Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry. 2009;80(8):832-8. [Crossref]  [PubMed]
  24. Walsh RJ, Amato AA. Toxic myopathies. Neurol Clin. 2005;23(2):397-428. [Crossref]  [PubMed]
  25. Mammen AL. Toxic myopathies. Continuum (Minneap Minn). 2013;19(6 Muscle Disease):1634-49. [Crossref]  [PubMed]  [PMC]
  26. Pasnoor M, Barohn RJ, Dimachkie MM. Toxic myopathies. Curr Opin Neurol. 2018;31(5):575-82. [Crossref]  [PubMed]
  27. Willis JK, Tilton AH, Harkin JC, Boineau FG. Reversible myopathy due to labetalol. Pediatr Neurol. 1990;6(4):275-6. [Crossref]  [PubMed]
  28. McGrath ER, Doughty CT, Amato AA. Autoimmune Myopathies: Updates on Evaluation and Treatment. Neurotherapeutics. 2018;15(4):976-994. [Crossref]  [PubMed]  [PMC]
  29. Cobos GA, Femia A, Vleugels RA. Dermatomyositis: An Update on Diagnosis and Treatment. Am J Clin Dermatol. 2020;21(3):339-53. [Crossref]  [PubMed]
  30. Zhang L, Wu G, Gao D, Liu G, Pan L, Ni L, et al. Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(5):e0155381. [Crossref]  [PubMed]  [PMC]
  31. Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M. Idiopathic inflammatory myopathies: a review. Intern Med J. 2021;51(6):845-52. [Crossref]  [PubMed]
  32. Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016;87(10):1038-44. [Crossref]  [PubMed]
  33. Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med. 2016;374(7):664-9. [Crossref]  [PubMed]
  34. Rodolico C, Bonanno C, Pugliese A, Nicocia G, Benvenga S, Toscano A. Endocrine myopathies: clinical and histopathological features of the major forms. Acta Myol. 2020;39(3):130-5.
  35. Vignesh G, Balachandran K, Kamalanathan S, Hamide A. Myoedema: A clinical pointer to hypothyroid myopathy. Indian J Endocrinol Metab. 2013;17(2):352. [Crossref]  [PubMed]  [PMC]
  36. Salih M, van Kinschot CMJ, Peeters RP, de Herder WW, Duschek EJJ, van der Linden J, et al. Thyrotoxic periodic paralysis: an unusual presentation of hyperthyroidism. Neth J Med. 2017;75(8):315-20.
  37. Hendy GN, Cole DEC, Bastepe M. Hypoparathyroidism and Pseudohypoparathyroidism. 2017 Feb 19. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
  38. Gupta A, Gupta Y. Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 2013;17(5):913-6. [Crossref]  [PubMed]  [PMC]
  39. Kallen PS, Louie JS, Nies KM, Bayer AS. Infections myositis and related syndromes. Semin Arthritis Rheum. 1982;11(4):421-39. [Crossref]  [PubMed]
  40. Reveille JD. The changing spectrum of rheumatic disease in human immunodeficiency virus infection. Semin Arthritis Rheum. 2000;30(3):147-66. [Crossref]  [PubMed]
  41. Cuturic M, Hayat GR, Vogler CA, Velasques A. Toxoplasmic polymyositis revisited: case report and review of literature. Neuromuscul Disord. 1997;7(6-7):390-6. [Crossref]  [PubMed]